Corvus Pharmaceuticals, Inc. (CRVS) EPS Estimated At $-0.63

July 11, 2018 - By Catherine Diaz

Analysts expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to report $-0.63 EPS on August, 2.They anticipate $0.10 EPS change or 13.70 % from last quarter’s $-0.73 EPS. After having $-0.63 EPS previously, Corvus Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. It closed at $11.04 lastly. It is down 3.14% since July 12, 2017 and is uptrending. It has underperformed by 9.43% the S&P500.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. The company has market cap of $322.30 million. The Company’s lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. It currently has negative earnings. The firm is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase.

Another recent and important Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) news was published by which published an article titled: “Corvus Pharmaceuticals Remains A High-Risk Investment” on June 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.